Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-07-31
Item 8.01
The WUTC issued an order approving a multi-year rate increase for NW Natural's Washington operations, authorizing $20.1 million in Year 1 revenue increases (effective August 2026), $7.5 million in Year 2, and $7.4 million in Year 3. This is a material regulatory outcome affecting the company's revenue and rate base, but it is fundamentally a favorable regulatory approval rather than a crisis, covenant breach, or other specific event type. The disclosure centers on the operational and financial impact of approved rate recovery, making it an operational/regulatory milestone rather than a financial obligation event (debt_issuance) or other category.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-31
EX-99.1
This press release announces VERAXA's patent portfolio strengthening, including first BiTAC-related patent applications filed in H1 2026 covering composition of matter, payload platforms, click chemistry, and conjugation technology. The company now holds over 50 granted patents across 26 families in 14 countries, with recently filed applications expected to protect core technology through 2047. This is a material operational/strategic milestone for a biotechnology company whose competitive advantage depends on intellectual property protection of its core BiTAC-TCE and BiTAC-ADC platforms.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-31
Grupo Cibest announces that Nequi S.A. Compañía de Financiamiento will begin independent operations on September 1, 2026, following authorization from Colombia's Financial Superintendency (disclosed November 6, 2025). This represents a material operational restructuring within the group—the separation of Nequi from Bancolombia as an independent financial entity with transferred assets, liabilities, and contracts—that would affect a reasonable investor's assessment of the registrant's business structure and operations, though it does not fit a specific named event type (not M&A, not a discrete departure or appointment, not a financial obligation).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
IRSA announced a barter agreement for a 2,360 sqm lot with 4,500 sqm total saleable area as part of the "Ramblas del Plata" real estate development project, valued at USD 4 million. This is a material operational/strategic transaction involving property acquisition and project advancement, but does not fit the specific categories of M&A activity (no acquisition of a company or material business unit), debt issuance, or other defined event types. The disclosure reflects progress on a significant real estate development initiative that would affect investor assessment of the company's operational pipeline and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-30
Item 8.01
The disclosure announces a significant customer order for RAD's autonomous security products—12 RIO Mini units and 12 ROSA units with SARA licenses—described as "RAD's largest single order to date for a data center construction application." This is a material operational/commercial milestone representing a major contract win, but it does not fit the specific categories of earnings release, M&A activity, debt issuance, or other defined event types. The order demonstrates business traction and revenue opportunity, making it material to investors assessing the company's operational performance and market adoption of its products.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
Integra Resources filed a Feasibility Study Technical Report and updated Life of Mine Plan for the Florida Canyon Mine, disclosing a 74% increase in Proven and Probable Mineral Reserves to 1.19 million ounces of gold, an 8-year operating mine life, 17% increase in average annual gold production to approximately 82,000 ounces, and an after-tax NPV of $601 million with approximately $0.8 billion of after-tax free cash flow.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
The exhibit discloses a drone strike on the Company's Suezmax tanker Nissos Sifnos while loading at the Caspian Pipeline Consortium terminal on July 30, 2026. Although the crew remained safe and the vessel sustained only minor damages with no spill, the incident represents a material operational and security event affecting one of the Company's ten Suezmax tankers. This is an operational disruption and security incident that would affect a reasonable investor's assessment of operational risks and vessel safety, but does not fit the specific cybersecurity_incident category (which applies to information systems breaches) or other named event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
Tvardi announced the selection of ulcerative colitis as the initial indication for its lead candidate TTI-109, following completion of a Phase 1 healthy volunteer study. This represents a material strategic and operational milestone in the company's clinical development pathway—the decision to advance a specific product candidate into a defined therapeutic area with planned IND clearance and Phase 2 initiation in 2027. While not a traditional M&A, earnings, or governance event, this disclosure of a major clinical development decision and the supporting Phase 1 data would affect a reasonable investor's assessment of the company's pipeline progress and near-term catalysts.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
Replimune disclosed attendance at an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on July 30, 2026, to discuss a BLA resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment. This is a material regulatory milestone for a clinical-stage biopharmaceutical company—the advisory committee meeting represents a critical juncture in the FDA approval process for a breakthrough-designated therapy. While not a formal approval or denial, the meeting and supporting presentation materials constitute a significant operational and regulatory event that would affect investor assessment of the company's pipeline progress and near-term catalysts.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This press release announces Instinct Bio's strategic decision to launch a subscription-model beauty clinic business under its Japanese brand "GENRÊVER CLINIC" in Indonesia, with an initial investment of approximately US$1 million across five clinics. The disclosure describes a new business line and market entry strategy positioned as a gateway to the company's regenerative-medicine focus. While this is a material operational and strategic initiative that would affect a reasonable investor's assessment of the company's business direction and capital deployment, it does not fit neatly into the specific event categories (it is neither M&A, a discrete executive change, nor a financial obligation); accordingly, it is classified as an operational/strategic business event under `operational_other`.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
Fortuna Mining announces approval of a 30% capacity expansion of its Séguéla Gold Mine in Côte d'Ivoire, including processing facility upgrades, infrastructure improvements, and development of the Sunbird underground mine. The project involves $109 million in estimated capital expenditure and is expected to increase annual gold production to over 200,000 ounces with a 2.5-year payback period. This is a material operational and strategic business decision—a significant capital project and mine development initiative—that does not fit the specific categories of M&A, workforce reduction, or other named operational types, making it an operational_other event material to investors assessing the company's growth strategy and capital allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 8.01
The FDA Advisory Committee voted 9-3 against the effectiveness of Deramiocel for cardiomyopathy in DMD patients, a material regulatory setback for Capricor's lead product candidate. While the vote is non-binding and the FDA will make the final decision by August 22, 2026, this negative advisory committee recommendation materially affects the company's regulatory pathway and investor assessment of approval prospects. This is a regulatory/operational milestone that does not fit the specific categories of restatement, auditor change, going concern, impairment, or litigation, but clearly represents a material operational event affecting the company's primary development program.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
Stantec has been awarded a US$150 million joint venture contract by the U.S. Army Corps of Engineers for a coastal resilience project in Charleston, with a total program value of US$1.2 billion. This is a material operational and strategic business event—a significant contract award that demonstrates the company's market position and growth opportunity in coastal infrastructure, but it does not fit the specific categories of M&A activity, debt issuance, or other named event types. The disclosure emphasizes Stantec's leadership and strengthened position to grow work with USACE and regional partners, making it material to investor assessment of the company's business prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This exhibit is a quarterly business update disclosing multiple operational and strategic developments: delivery of a C-sample to Panasonic (a key commercialization milestone), completion of a capital raise (A$21.66 million institutional placement and SPP), divestiture of the BTS division to former CEO Dr. Chris Burns, CFO transition with Ron Edmonds as interim CFO, and updates on U.S. government trade policy and incentives affecting the graphite AAM industry. While the exhibit contains elements of several event types (capital raise, divestiture, executive transition), it is fundamentally a comprehensive operational and strategic update rather than a discrete event fitting a single category. The Panasonic C-sample delivery and capital raise are material to investors assessing commercialization progress and funding, but the exhibit as a whole is a mixed operational disclosure without a single dominant event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-30
Item 8.01
EyePoint announced completion of enrollment in both pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema, with over 480 patients enrolled ahead of schedule in five months. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress toward potential regulatory approval and commercialization of its lead product candidate. The event is operational/strategic in nature—a major clinical program milestone—rather than fitting into financial, governance, legal, or terminal categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
Evommune announced initiation of a Phase 2b clinical trial for EVO756, a MRGPRX2 inhibitor in migraine prophylaxis, with top-line data expected in 2027. This is a material operational and clinical development milestone for a clinical-stage biotech company, representing significant progress in its pipeline. While not fitting a specific named event type, this clinical trial initiation is clearly an operational/strategic business event material to investors assessing the company's development progress and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This exhibit is a comprehensive investor presentation disclosing POSCO Holdings' "Value-Up Plan" — a multi-year strategic transformation initiative covering portfolio evolution (Triple-Core Portfolio: Steel, Lithium+α, Energy), capital allocation targets (KRW 29.1 trillion investment plan through 2028), shareholder return policy (35-40% of adjusted net profit), and financial targets (ROIC 1.9% to 5.8%, PBR 0.4 to 1.0, revenue CAGR 8.4%). While the presentation touches on governance (board communication, treasury share cancellation) and financial strategy (dividend policy, asset restructuring), its primary substance is operational and strategic — the company's business transformation roadmap, overseas expansion, and resource diversification. This is material to investors as it articulates the company's medium-term strategic direction and capital deployment priorities, but does not fit neatly into discrete event categories (not an earnings release, M&A, impairment, or governance action), making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This press release announces a "design win" — a customer selection and initial order for Mobilicom's integrated cybersecurity, electronic warfare, and datalink solutions for AI-enabled autonomous weapon systems. The disclosure describes a material commercial contract win with an Israeli defense technology company, including product delivery and initial revenue. While this is a significant business development, it does not fit neatly into the standard event taxonomy (not M&A, not a financial result, not a governance change, not a restructuring). It is clearly operational — a material contract or partnership milestone — making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This press release discloses a material operational and strategic update on the Rain protocol's trading metrics—$860MM in trading volume with 622% month-over-month growth in July 2026—and forward projections for the protocol and Enlivex's treasury strategy. While the disclosure relates to the company's digital asset treasury operations and prediction markets exposure (a core strategic initiative), it does not fit neatly into standard event categories (not earnings, not M&A, not a periodic report). The material growth metrics and forward guidance on the Rain protocol's trajectory and fee generation support classification as an operational milestone affecting investor assessment of the company's treasury strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 8.01
Ambow announced the general availability of the HybriU AI Adaptive Course Generation Platform, a new product launch representing the third HybriU product release in 2026. This is a material operational and strategic business event—a significant product milestone that extends the company's Knowledge Intelligence strategy and targets the $458 billion global corporate training market. While not fitting a specific named category, this product launch is clearly operational/strategic in nature and material to investors assessing the company's growth trajectory and market positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 3.03
Game Your Game Inc. commenced trading of its common stock on the Nasdaq Capital Market under ticker "GYGY" on July 30, 2026, marking the company's transition from private to public status via direct listing. This is a significant capital-markets and operational milestone affecting the company's public status, investor base, and security holder rights.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
This press release announces positive safety results from Part A of an FDA-regulated Phase I/II clinical trial for CMND-100, a proprietary drug candidate for Alcohol Use Disorder. All 24 participants completed treatment with no serious adverse events and consistent tolerability across all dose escalations (20 mg to 160 mg). While this is a clinical milestone for a biotech company, it does not fit the discrete event categories (not earnings, M&A, executive changes, impairment, or litigation). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking of its lead asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
This press release announces a strategic partnership between Solmate Infrastructure and Kraken Institutional to enhance staking economics and optimize the Company's Solana validator infrastructure. The partnership is described as "another major milestone" in executing Solmate's long-term digital infrastructure strategy and is designed to "maximize long-term recurring revenue potential." While this is a material operational and strategic business event affecting the Company's core infrastructure business model, it does not fit the specific categories of M&A activity, debt issuance, or other named event types—it is a material partnership/commercial arrangement that would affect a reasonable investor's assessment of the Company's operational strategy and revenue prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
ImmunityBio announced that the Emirates Drug Establishment (EDE) of the UAE granted marketing authorization for ANKTIVA across two indications (BCG-unresponsive NMIBC and metastatic NSCLC), expanding its global regulatory footprint to 34 countries. This is a significant regulatory milestone and product approval event that would materially affect investor assessment of the company's commercial prospects and pipeline progress, but it does not fit neatly into the specific financial, governance, or legal categories—it is a strategic operational/commercial achievement in product development and regulatory approval.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 1.01
Remora Capital entered into a loan sourcing and services agreement with Sound Point Capital Management on July 27, 2026, establishing an ongoing operational arrangement whereby Sound Point will identify investment opportunities and the Company will pay quarterly fees based on aggregate investment value (0.65%–0.80% per annum). This is a material definitive agreement governing a core business service (investment sourcing) for an investment company, but it does not constitute a discrete M&A transaction, debt issuance, or other specifically-named event type; it is best classified as an operational business arrangement.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
Coastal Financial Corporation furnished investor presentation slides for Q2 2026 under Regulation FD Disclosure (Item 7.01). While the presentation contains quarterly financial highlights and operational metrics, the Item 7.01 disclosure itself is a routine furnishing of presentation materials for investor meetings. However, the underlying content reveals material operational developments: a $22.8 million provision for credit losses and $46.0 million valuation adjustment related to a single partner, loan portfolio growth of 9.0% QoQ, and strategic shifts in partner economics. The disclosure is primarily operational/strategic in nature rather than a specific event type (not earnings release, not M&A, not a restatement), making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
This is a commercial update on CLINUVEL's vitiligo market strategy and competitive positioning for SCENESSE® (afamelanotide). The document benchmarks the company's product against standard-of-care NB-UVB phototherapy and competing JAK inhibitors, and announces preparation for a pivotal CUV107 trial anticipated to start November 2026, with CUV105 topline results expected December 2026. While not a discrete event like an M&A transaction or earnings release, this strategic market assessment and trial timeline disclosure materially informs investors about the company's clinical development pathway and competitive landscape in an emerging therapeutic area.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
Ming Shing announces entry into a strategic cooperation framework agreement (MOU) with Meal Though Seasons HK Limited to apply graphene thermal management technology to agricultural supply chains. While the MOU is explicitly non-binding and creates no binding revenue commitments or financial obligations, it represents a material strategic business development that could lead to future equity investment, joint ventures, or M&A activity. The disclosure is operational in nature—a partnership framework exploring technology application—and does not fit the specific categories of ma_activity (no binding transaction), debt_issuance, or other defined event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-30
EX-99.1
Core AI announces the formation of Z Studio, a new dedicated business unit focused on developing and scaling AI-powered consumer applications across multiple vertical markets. This represents a material strategic expansion of the company's business model beyond its existing AI infrastructure and gaming operations, establishing "an additional long-term growth platform." The announcement describes organizational structure, development activity (16 teams, 129 prototype builds, 27 live market-validation campaigns), and current products (HomeGPT, AICalfit, PlantCare), indicating a significant operational and strategic initiative that would affect a reasonable investor's assessment of the company's growth trajectory and business diversification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-30
Item 7.01
The disclosure is a project status update on the Lone Tree Plant refurbishment, a cornerstone asset in the Company's Phase 1 development plan. The update confirms the project remains on schedule and on budget with specific milestones (first gold pour by year-end 2027), procurement progress (50% awarded), and capital status ($430 million total estimate with minimal contingency drawdown). This is a material operational/strategic milestone for a mining company's development plan, but does not fit the specific categories of M&A, workforce reduction, or other named operational events—it is a project progress disclosure that would affect investor assessment of execution risk and capital deployment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-30
Item 8.01
Better Home & Finance executed an amendment to its broker agreement with Intuit Credit Karma to expand the partnership and offer HELOC products to Credit Karma's 140 million consumer base under the "Credit Karma Home Loans powered by Better" brand. The company explicitly states it expects this offering to "contribute meaningfully to the Company's loan volume and revenue growth over the following several quarters," indicating a material strategic partnership expansion with significant revenue implications. This is a material operational/strategic business event involving a partnership expansion rather than a discrete financial transaction, M&A activity, or other named event type.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-30
EX-99.1
This press release announces the launch of ElvaPulse™ 1500, a new high-power stationary battery energy storage system platform designed for data centers and mission-critical applications. The disclosure describes a material product launch with significant technical specifications (up to 7 MW continuous power, 2.88 MWh capacity), targeted Q2 2027 deliveries from the Jamestown facility, and active customer discussions. While not fitting the specific operational categories (no M&A, workforce reduction, or contract milestone), this represents a material strategic business event—the introduction of a new product platform addressing a major market opportunity (AI data center power demand projected to double by 2030)—that would affect a reasonable investor's assessment of the company's growth prospects and revenue potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 65%
filed 2026-07-30
Item 1.01
The Company entered into a material definitive agreement disclosed under Item 1.01; the specific nature of the agreement (contract, partnership, supply arrangement, or other operational arrangement) cannot be determined from the Item classification alone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-29
Item 8.01
Churchill Downs is disclosing a comprehensive strategic review and exploration of selling eight wholly owned regional gaming properties, including major assets like Calder Casino, Hard Rock Hotel & Casino in Iowa, and del Lago Resort and Casino. This is a material operational and strategic business event involving potential divestiture of significant assets, but the company has not yet committed to any transaction. The disclosure fits operational_other because it involves a strategic business decision and potential asset sales that do not yet constitute a completed M&A transaction (which would be ma_activity), but rather an ongoing exploration process that would materially affect investor assessment of the company's future direction and capital allocation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-29
EX-99.1
This press release announces a 32% increase in mineral reserves at Karlawinda, a cornerstone asset contributing US$8.9 million in 2025 revenue to Elemental, along with an expansion nearing completion expected in Q3 2026 and a 10-year mine-life extension. While the event is operational in nature (reserve increase and expansion progress at an underlying asset), it is material to Elemental's investors as it directly enhances the long-term value and production profile of a key royalty asset without additional capital from the Company. The disclosure does not fit discrete event categories like M&A, impairment, or earnings release, but rather represents a material operational milestone affecting the value of Elemental's portfolio.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-29
EX-99.1
This press release announces BEACON-US, a comprehensive scientific research initiative evaluating high-volume hemodiafiltration (HVHDF) outcomes in U.S. clinical practice. The disclosure describes an operational and strategic business initiative—expanding access to a therapy across the U.S., building on international evidence, and supporting the company's "FME Reignite strategy" for growth and innovation. While the announcement includes clinical data and references to published studies, the core event is the launch of a research program and therapy rollout, which is operational/strategic in nature and does not fit the specific event types (e.g., earnings_release, ma_activity, or exec changes). The initiative is material because it reflects a significant strategic commitment to a key therapeutic area and supports the company's growth strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-29
Item 8.01
The disclosure centers on two operational/regulatory developments: (1) publication of Phase 3 HOPE-3 trial results in The Lancet with an update to the LVEF statistical model (p-value revised from 0.04 to 0.09), and (2) completion of an FDA BIMO inspection with a Form 483 observation regarding documentation and vendor oversight. While the trial publication is a significant clinical milestone for a biotech company with a pending BLA (PDUFA target August 22, 2026), and the FDA inspection observation could signal regulatory risk, neither event fits the specific taxonomy categories. The statistical model revision is material to investors assessing the strength of the regulatory submission, but this is a clinical/operational disclosure rather than a restatement or going-concern issue. The BIMO observation, while potentially concerning, does not constitute a covenant breach, delisting risk, or other terminal event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-29
EX-99.1
Titan announced a non-binding Letter of Intent with a U.S. aerospace and defense manufacturer for supply of natural graphite from its planned New York Kilbourne Graphite Project. This represents a material strategic business milestone—securing early customer validation and building the commercial order book for a major new product line—but does not fit the discrete event categories (M&A, debt, equity issuance, etc.). The LOI is explicitly non-binding and subject to multiple conditions, yet the announcement of customer qualification and commercialization progress for a critical minerals project is operationally significant to a reasonable investor assessing the company's development trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-29
EX-99.1
The press release announces the successful closure of an FDA inspection of Alvotech's manufacturing facility in Reykjavik with a "Voluntary Action Indicated" (VAI) classification. This is a regulatory milestone affecting the company's ability to manufacture and advance its biosimilar pipeline toward FDA approval. While not a discrete event type like exec_appointment or debt_issuance, it is a material operational and regulatory development that would affect a reasonable investor's assessment of the company's manufacturing compliance and regulatory progress, particularly given the company's focus on biosimilar development and the importance of FDA manufacturing inspections to product approvals.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-29
EX-99.1
This press release announces a material update to the Lobo-Marte gold development project in Chile, disclosing updated feasibility study economics (NPV of $4.3 billion, IRR of 26%, ~350,000 oz. annual production at ~$1,000/oz. AISC), permitting progress (EIA accepted by Chilean authorities in Q2 2026), and capital expenditure plans (~$1.8 billion over three years). The disclosure covers project development strategy, mine planning, and operational milestones rather than a discrete M&A transaction, financial restatement, or executive change. This is a material operational/strategic update affecting the company's long-term production profile and capital allocation, but does not fit the specific event types for M&A, earnings release, or other defined categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-29
Item 7.01
The disclosure announces the successful initiation of a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a transition from regulatory preparation into active clinical execution. This is a material operational and clinical milestone for a clinical-stage biotechnology company, but does not fit the specific named event types (earnings, executive changes, M&A, impairment, etc.). The event is clearly operational/strategic in nature—a significant clinical development milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-29
Item 7.01
Private Bancorp of America announced that its Form 10 Registration Statement was declared effective by the SEC and that its common stock has been approved for listing on the Nasdaq Global Select Market, with trading commencing July 30, 2026 under ticker "PBAM." This is an uplisting from the OTCQX market after 13+ years. While this is a significant corporate milestone affecting market visibility, liquidity, and capital access, it does not fit the specific event types in the taxonomy (not M&A, not a governance change, not a financial obligation). The event is clearly operational/strategic in nature and material to investors, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-29
EX-99.1
PolyPid announced FDA acceptance of its NDA for D-PLEX100 with Priority Review status and an accelerated PDUFA target action date of November 28, 2026. This is a material regulatory milestone that triggers a $15 million milestone payment from commercial partner Azurity and represents significant progress toward potential market approval. While this is a regulatory/operational event rather than a discrete financial event (earnings, debt, M&A), it materially affects investor assessment of the company's development trajectory and near-term commercialization prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-07-29
EX-99.1
SciSparc's board announced a strategic decision to target the agentic AI market and establish a Scientific Advisory Board for AI and cybersecurity, representing a material shift in the company's business focus and strategic direction.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-07-29
EX-99.2
NeuroThera Labs, SciSparc's majority-owned subsidiary, completed internal validation of its proprietary quantum computing platform (CliniQuantum) for clinical data analytics, demonstrating successful validation of a quantum sampling workflow on a hybrid quantum-classical platform with potential applications to drug development and clinical trials.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-29
Item 8.01
Costco's discontinuation of the Company's FOCUSfactor products represents a material loss of a major customer (58% of FY2025 net revenue for over 16 years), which is an operational/commercial event with severe financial consequences. The Company explicitly states it expects a "material adverse effect" on business, operations, liquidity, and financial condition. This is a significant customer loss that does not fit the specific categories of M&A, impairment, or litigation, but clearly qualifies as a material operational event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-29
The filing discloses receipt and release of a conceptual engineering study (Hatch Report) for Ramaco's exploratory Brook Mine critical minerals project, along with a shareholder letter and press release discussing the project's latest developments. This represents a material operational/strategic milestone—the advancement of a greenfield rare earth and critical minerals extraction project from concept to initial assessment phase—but does not fit neatly into any specific event category (not M&A, not a contract, not a regulatory approval). The disclosure is material to investors assessing the company's strategic direction and project viability.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-29
Item 7.01
Aeluma announced entry into a Letter of Intent with the U.S. Department of Commerce for up to $30 million in CHIPS and Science Act funding to advance R&D of its semiconductor manufacturing platform. This is a material strategic and operational milestone—a government funding award that would accelerate commercialization and support the company's technology development—but does not fit neatly into the specific event categories (not M&A, not debt issuance, not a dilutive equity offering per se, though equity will be issued). The funding is conditional on execution of definitive documents and milestone achievement, making it a significant operational/strategic event rather than a completed transaction or financial obligation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-29
Item 8.01
Eton Pharmaceuticals announced submission of a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI's indication to younger pediatric patients (under age five) with adrenal insufficiency. This is a material regulatory milestone for an existing commercial product—the company is pursuing label expansion to access a larger market segment ("the largest need for an FDA-approved oral liquid hydrocortisone remains with children under age five"). While this is clearly operational/strategic in nature and material to investors assessing the company's growth prospects, it does not fit neatly into the specific event categories (not an earnings release, M&A, impairment, litigation, etc.), making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-29
Item 8.01
The disclosure announces a clinical trial milestone—surpassing the enrollment midpoint of the NANOPULSE-AF pivotal IDE study for the nPulse Cardiac Catheter System. This is a material operational/strategic event for a medical device company, as it signals progress toward regulatory approval and commercialization of a key product candidate. The event does not fit the specific categories of earnings release, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction; it is a clinical development milestone that would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory prospects.
View raw filing on EDGAR →